

I BACKGROUND INFORMATION ON THE PROCEDURE

1. Submission of the dossier

The company Janssen Cilag International NV submitted in 2013 an application for INTELENCE 25 mg tablets¹ (HA600) to be assessed with the aim of including INTELENCE in the list of prequalified medicinal products for the treatment of HIV/AIDS.

INTELENCE was assessed according to the ‘Procedure for Assessing the Acceptability, in Principle, of Pharmaceutical Products for Purchase by United Nations Agencies’ by the team of WHO assessors. The assessors are senior experts, mainly from national authorities, invited by WHO to participate in the prequalification assessment process.

Based on the data submitted the team of assessors advised that INTELENCE is included in the list of prequalified medicinal products. INTELENCE was listed on 21 October 2013.

INTELENCE ‘s conformance to the requirements of the current SRA guideline was re-evaluated by the team of WHO assessors.

2. Steps taken in the re-evaluation of the product

February 2022	WHO letter of request for requalification was sent to the applicant.
April 2022	The application letter was received.
September 2022	The assessment team reviewed the submitted data and further information was requested
January 2023	The applicant’s response letter was received.
April 2023	The assessment team reviewed the submitted data and further information was requested
September 2023	The applicant’s response letter was received.
November 2023	The submitted data were reviewed and found to comply with the relevant WHO requirements.
26 November 2023	Requirements of requalification were met. INTELENCE 25 mg tablets remained on the list of prequalified medicinal products.

¹ Trade names are not prequalified by WHO. This is the national medicines regulatory authority’s responsibility. Throughout this WHOPAR the proprietary name is given as an example only.